AbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativa (ABBV:NYSE)
AbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativa (ABBV:NYSE) Seeking Alpha
Covered in this story
Analyst targets on AbbVie
- UBS: $276 → $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: $263 → $300 by Sep 2027 · Outperform via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 22 Jun 2026.
Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.